*Promoted by Sica Media

MAIA is Showing Incredible Strength in a Weak Market. 

All Eyes on This Move Today

This has been an absolutely wild market lately, don’t you agree?

Yesterday, I shared this chart on the QQQ with members just to show how violent the moves have been, both up and down…

Of course, now QQQ has bounced $5 from yesterday’s lows… and who knows where it is going from here?

While this can be an incredibly tough market to hold stocks for more than a couple of days, it presents some of the best trading opportunities I have seen in a long time when you catch the right direction.

If there is one thing you’ll notice in the chart above… ALL of those moves were predictable if you simply looked for a break above/below my “magical” 20-hour line.

My “Gamma Trigger” signal has absolutely crushed the market lately (go back and read my weekend emails for more details.)

Today, I have another extremely time-sensitive idea I want to share with you.

Pull up MAIA Biotechnology, Inc. (MAIA) on your platform and look at it right away.

What you’ll immediately see is that even with the market carnage yesterday, MAIA started to break out into a “Gamma Trigger” move.

Yeah, there was actually a stock showing some strength in the midst of the wreckage yesterday!

Of course, you never know what will happen in the future, but based on the moves you can see in the past for MAIA, I think this stock has incredible potential today.

Remember – stock moves seem to happen very quickly right now.  If you want to catch the “meat of the move,” you need to start watching as early as possible.

If you look back at some of my recent ideas over the last few weeks, you’ll see that some of these have led to fast moves of 20%, 50%, and even over 200% in a very short period of time.

I think MAIA has the potential to become one of the biggest movers in the entire market today.

I know it sounds crazy.  But, when you look at the potential here and the chart setup like it is right now, I think it is very possible.

I don’t think you should sleep on this idea.  

Take a close look at it today and see if you like it as much as I do.

MAIA Biotechnology, Inc. (MAIA) is a clinical-stage biopharmaceutical company exploring genuinely groundbreaking cancer treatments.

Its lead asset — called THIO — “is the only direct telomere targeting agent currently in clinical development.”

Its action in cancer treatment has been featured in renowned publications such as Cancer Cell and Nature.

Here’s how it works…

There’s an enzyme called telomerase that’s present in 85% to 90% of human cancers and that “contributes significantly to the proliferation and reproductive immortality of cancer cells.”

According to the company, “THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death.”

On top of killing the cancer cells directly, THIO — coupled with an immune checkpoint inhibitor — seems to produce an immune memory specific to cancer cells “where the immune system [continues] to be active against the cancer cells after extended periods of time, with no additional treatment.”

If you know anything about cancer, you know that maintaining remission is the truly critical part of therapy, and THIO is showing promise in that respect.

On February 22, MAIA announced the completed enrollment of its Phase 2 clinical trial for THIO in cases of non-small cell lung cancer (NSCLC), noting that “preliminary data has demonstrated unprecedented rates of disease control and response to date, and we look forward to the long-term efficacy results as we continue to monitor the enrolled patients in the upcoming months.”

The company is expecting this trial to be the “first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment.”

MAIA notes that NSCLC is “the largest tumor type globally by mortality (1.7 million deaths annually) and dollar sales ($34 billion annually).”

However, it appears that THIO may have applications well beyond NSCLC…

For instance, it has been granted three Orphan Drug Designations (ODD) by the FDA for “hepatocellular carcinoma (the dominant histology of primary liver cancers, ~90%), small cell lung cancer (the deadliest type of lung cancer), and malignant gliomas (the deadliest group of brain cancers, including glioblastomas).”

These designations afford the company seven years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing.

In an upcoming second clinical trial, MAIA will be pitting THIO against the likes of small cell lung cancer, liver cancer, and colorectal cancer.

On top of all this, MAIA is developing a second generation of THIO-derived drugs. They’ve developed more than 80 to date, with three U.S. patent applications.

According to the company, “Preclinical studies of several of these agents have shown highly significant anti-cancer efficacy at low dose levels in multiple in vivo and in vitro models.”

For a more detailed breakdown of MAIA’s trial progress and drug pipeline, check out company CEO Vlad Vitoc’s Letter to Shareholders released just yesterday.

Whatever you do, make sure that you come to the market each and every day with a solid game plan that fits your unique risk tolerance and of course, never trade with money that you can’t afford to lose.  Have a stop loss, and profit target that is right for you.

Bottom lineMAIA is showing me incredible strength in a weak market right now. With a history of massive moves in the past, I am excited to see what this stock holds for us today!

To Your Success,

Jeff Bishop

👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!).  Don’t miss out!

*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.



*PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on for a one day marketing program. Raging Bull has previously been paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15 through November 18, 2023. Raging Bull has previously been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of MAIA Biotechnology, Inc, increased trading volume, and possibly an increased share price of MAIA Biotechnology, Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in MAIA Biotechnology, Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.
SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.